CCL

Összesen 15 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM090867
Első szerző:Al-Chalabi, Ammar
Cím:Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis / Al-Chalabi Ammar, Heunks Leo M. A., Papp Zoltán, Pollesello Piero
Dátum:2019
ISSN:0160-2446
Megjegyzések:Levosimendan is a calcium sensitizer that promotes myocyte contractility through its calcium-dependent interaction with cardiac troponin C. Administered intravenously, it has been used for nearly 2 decades to treat acute and advanced heart failure and to support the heart function in various therapy settings characterized by low cardiac output. Effects of levosimendan on noncardiac muscle suggest a possible new application in the treatment of people with amyotrophic lateral sclerosis (ALS), a neuromuscular disorder characterized by progressive weakness, and eventual paralysis. Previous attempts to improve the muscle response in ALS patients and thereby maintain respiratory function and delay progression of disability have produced some mixed results. Continuing this line of investigation, levosimendan has been shown to enhance in vitro the contractility of the diaphragm muscle fibers of non-ALS patients and to improve in vivo diaphragm neuromuscular efficiency in healthy subjects. Possible positive effects on respiratory function in people with ALS were seen in an exploratory phase 2 study, and a phase 3 clinical trial is now underway to evaluate the potential benefit of an oral form of levosimendan on both respiratory and overall functions in patients with ALS. Here, we will review the various known pharmacologic effects of levosimendan, considering their relevance to people living with ALS.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Cardiovascular Pharmacology. - 74 : 5 (2019), p. 389-399. -
További szerzők:Heunks, Leo M. A. Papp Zoltán (1965-) (kardiológus, élettanász) Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM070110
Első szerző:Altenberger, Johann
Cím:Levosimendan in acute and advanced heart failure : an appraisal of the clinical database and evaluation of its therapeutic applications / Altenberger J., Gustafsson F., Harjola Veli-Pekka, Karason K., Kindgen-Milles D., Kivikko M., Malfatto G., Papp Z., Parissis J., Pollesello P., Pölzl G., Tschöpe C.
Dátum:2018
ISSN:0160-2446
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Cardiovascular Pharmacology. - 71 : 3 (2018), p. 129-136. -
További szerzők:Gustafsson, Finn Harjola, Veli-Pekka Karason, Kristian Kindgen-Milles, D. Kivikko, Matti Malfatto, Gabriella Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pollesello, Piero Pölzl, Gerhard Tschöpe, Carsten
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM020345
Első szerző:Bajza Ágnes (biológus)
Cím:Development of insulin resistance by nitrate tolerance in conscious rabbits / Ágnes Bajza, Barna Peitl, József Nemeth, Róbert Porszasz, György Rabloczky, Péter Literati-Nagy, Judit Szilvassy, Zoltán Szilvassy
Dátum:2004
Megjegyzések:Clinical evidence has been raised to suggest that transdermal nitroglycerin increases the sensitivity of peripheral tissues to the hypoglycemic effect of insulin. In this study we determined whether development of tolerance to the hypotensive effect of nitroglycerin also resulted in tolerance to the insulin-sensitizing effect in rabbits. Intravenous glucose disposal and hyperinsulinemic euglycemic glucose clamp studies were performed on naive and hemodynamic nitrate tolerant conscious New Zealand white rabbits. These rabbits were exposed to continuous "patch on" with nitroglycerin (0.07 mg/kg/h) or placebo patches over 7 days. Nitroglycerin treatment of 7 days produced a lack of hypotensive response to a single intravenous bolus of 30 microg/kg nitroglycerin, which caused a significant decrease in mean arterial blood pressure in control rabbits. A six-hour exposure to transdermal nitroglycerin significantly increased insulin sensitivity determined by hyperinsulinemic (100 microU/ml) euglycemic (5.5 mmol/l) glucose clamping as compared with that seen in rabbits treated with placebo patches. A significant decrease in insulin sensitivity was observed in the nitroglycerin patch-treated animals both in the presence and after the removal of the last patch when the patches were applied over 7 days. We conclude that acutely nitrate patches improve insulin sensitivity whereas a 7-day chronic treatment schedule that results in hemodynamic nitrate tolerance also produces insulin resistance.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
insulin tolerance
nitrate tolerance
Megjelenés:Journal of Cardiovascular Pharmacology. - 43 : 3 (2004), p. 471-476. -
További szerzők:Peitl Barna (1972-) (orvos, farmakológus) Németh József (Pécs) Pórszász Róbert (1965-) (farmakológus, klinikai farmakológus) Rablóczky György Literati Nagy Péter Szilvássy Judit (1960-2022) (fül- orr- gégész) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM028198
Első szerző:Bajza Ágnes (biológus)
Cím:Block by nitrate tolerance of meal-induced insulin sensitization in conscious rabbits / Bajza Á., Németh J., Peitl B., Szilvássy Z.
Dátum:2011
ISSN:0160-2446
Megjegyzések:Hemodynamic nitrate tolerance has been shown to result in an insulin-resistant state. We studied whether nitrate tolerance induced by a 7-day continuous exposure to transdermal nitroglycerin influenced the meal-induced insulin sensitization phenomenon in rabbits. METHODS: Changes in insulin sensitivity in response to feeding in conscious rabbits were determined by rapid insulin sensitivity test, in both nitrate-tolerant and nitrate-intolerant animals. In a separate series of experiments with anesthetized rabbits with or without nitrate tolerance, the hyperinsulinemic euglycemic glucose clamping methods was used to study the effect of intraportal infusion of cholecystokinin (CCK) on whole-body insulin sensitivity. RESULTS: Rabbits with normal feeding exhibited a 46 ± 6% increase in insulin sensitivity as compared with their matching fasting controls. A 7-day period of treatment with patches releasing 0.07 mg of nitroglycerin per hour yielded nitrate tolerance and a state of insulin resistance and no increase in insulin sensitivity in response to food. Intraportal infusion of CCK8 (0.3-3.0 mikrog/kg over 20 minutes) resulted in a dose-dependent increase in insulin sensitivity in normal but not in nitrate-tolerant, fasted anesthetized animals. CONCLUSIONS: Nitrate tolerance blocks both the meal-induced insulin sensitization phenomenon and the insulin-sensitizing effect of intraportal CCK.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Cardiovascular Pharmacology. - 58 : 5 (2011), p. 508-513. -
További szerzők:Németh József (1954-) (vegyész, analitikus) Peitl Barna (1972-) (orvos, farmakológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM015747
Első szerző:Dhalla, Naranjan S.
Cím:Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure / Naranjan S. Dhalla, Melissa R. Dent, Paramjit S. Tappia, Rajat Sethi, Barta Judit, Ramesh K. Goyal
Dátum:2006
Megjegyzések:It is now well known that congestive heart failure (CHF) is invariably associated with cardiac hypertrophy, and changes in the shape and size of cardiomyocytes (cardiac remodeling) are considered to explain cardiac dysfunction in CHF. However, the mechanisms responsible for the transition of cardiac hypertrophy to heart failure are poorly understood. Several lines of evidence both from various experimental models of CHF and from patients with different types of CHF have indicated that the functions of different subcellular organelles such as extracellular matrix, sarcolemma, sarcoplasmic reticulum, myofibrils, mitochondria, and nucleus are defective. Subcellular abnormalities for protein contents, gene expression, andenzyme activities in the failing heart become evident as a consequence of prolonged hormonal imbalance, metabolic derangements, and cation maldistribution. In particular, the occurrence of oxidative stress, development of intracellular Ca2+ overload, activation of proteasesand phospholipases, and alterations in cardiac gene expression result in changes in the biochemical composition, molecular structure, and function of different subcellular organelles (subcellular remodeling). Not only does subcellular remodeling appear to be intimately involved in the transition of cardiac hypertrophy to heart failure, the mismatching of the function of different subcellular organelles leads to the development of cardiac dysfunction. Although blockade of the renin-angiotensin system, sympathetic nervous system, and various other hormonal actions have been reported to produce beneficial effects on cardiac remodeling and heart dysfunction in CHF, the actions of various cardiac drugs on subcellular remodeling have not been examined extensively. Some recent studies have indicated thatboth the angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists attenuate changes in sarcolemma, sarcoplasmic reticulum, and myofibril enzyme activities, protein contents, and gene expression, and partly improve cardiac function in the failing hearts. It is suggested that subcellular remodeling is an excellent target for the development of improved drug therapy for CHF. Furthermore, extensive studies should investigate theeffects of different agents individually or in combination on reverse subcellular remodeling, cardiac remodeling, and cardiac dysfunction in various experimental models of CHF.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
congestive heart failure
cardiac remodeling
subcellular remodeling
cardiac drugs
cardiac hypertrophy
cardiac dysfunction
Megjelenés:Journal of Cardiovascular Pharmacology and Therapeutics. - 11 : 1 (2006), p. 31-45. -
További szerzők:Dent, Melissa R. Tappia, Paramjit S. Sethi, Rajat Barta Judit (1975-) (kardiológus) Goyal, Ramesh K.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

6.

001-es BibID:BIBFORM038424
Első szerző:Drimba László (farmakológus)
Cím:Beneficial Cardiac Effects of Cicletanine in Conscious Rabbits With Metabolic Syndrome / Drimba László, Hegedüs Csaba, Yin Din, Sári Réka, Németh József, Szilvássy Zoltán, Peitl Barna
Dátum:2012
ISSN:0160-2446
Megjegyzések:BACKGROUND AND PURPOSE: High-fat diet and consequent metabolic syndrome (MS) can lead to elevated risk for cardiac arrhythmias. This preclinical study was to investigate if cicletanine (CIC) could produce cardioprotective effects in conscious rabbits exhibiting the main symptoms of MS. METHODS: NZW rabbits that had undergone an 8-week-long cholesterol-enriched diet (1.5%) were instrumented with a pacemaker electrode and randomly assigned into 3 groups according to the oral treatment of either CIC (50 mg·kg) or sotalol (25 mg·kg) and their placebo b.i.d. over 5 days. Study groups were subjected to either "arrhythmia challenge" by programmed electrical stimulation in the "Arrhythmogenesis" study (N = 54) or global myocardial ischemia by rapid pacing in the "Ventricular Overdrive Pacing-induced Myocardial Ischemia" study (N = 18). The antiarrhythmic effect was evaluated by the establishment of the incidence of programmed electrical stimulation-induced arrhythmias. Proarrhythmia indicators (eg, QTc, Tpeak-Tend) were also measured to assess the cardiac safety profile of CIC. To evaluate the background of antiarrhythmic effect, cardiac cyclic nucleotide (cyclic 3',5'-guanosine monophosphate [cGMP], cyclic 3',5'-adenosine monophosphate [cAMP]) and nitric oxide content were determined. The antiischemic effect was characterized by change of intracavital ST segment. RESULTS: Cicletanine treatment significantly decreased the incidence of ventricular arrhythmias, increased cardiac cGMP and nitric oxide content and reduced cardiac cAMP level. Cicletanine did not modify significantly QTc and Tpeak-Tend interval. The ST-segment change in response to rapid pacing was reduced significantly by CIC. (P < 0.05). CONCLUSIONS: Cicletanine exerts beneficial cardiac effects in rabbits with symptoms of MS, which may be of influence with regard to the clinical application of the drug.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
cicletanine
cardiac arrhythmias
cardiac ischemia
metabolic syndrome
programmed electrical stimulation
cardiac nucleotides
nitric oxide
Megjelenés:Journal of Cardiovascular Pharmacology. - 60 : 2 (2012), p. 208-218. -
További szerzők:Hegedűs Csaba (1983-) (Molekuláris biológus, Cera-Med Kft. Debrecen) Yin, Din Sári Réka (farmakológus) Németh József (1954-) (vegyész, analitikus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Peitl Barna (1972-) (orvos, farmakológus)
Pályázati támogatás:NKFP_07-A2-2008-0260
EGYÉB
GOP-1.1.2-07/1-2008-0004
EGYÉB
GOP-1.1.1-07/1-2008-0032
EGYÉB
GOP-1.2.1-08-2009-0023
EGYÉB
OTKA-75965
OTKA
TÁMOP-4.2.2.- 08/1-2008-0014
TÁMOP
OM-00174/2008
EGYÉB
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM020336
Első szerző:Karsai Dénes
Cím:Effect of nucleoside transport blockade on the Interstitial adenosine level characterized by a novel method in guinea pig atria / Karsai, Dénes, Zsuga, Judit, Juhász, Béla, Dér, Péter, Szentmiklósi, András József, Tósaki, Árpád, Gesztelyi, Rudolf
Dátum:2006
Megjegyzések:Several accepted methods are available to estimate theadenosine (Ado) concentration of interstitial fluid ([Ado]ISF) in functioningheart, providing results spanning over nano- to micromolarconcentrations. This extremely large range points to the necessity ofnovel approaches for estimating [Ado]ISF or at least the alterationfrom basal [Ado]ISF. In the present study, the change in [Ado]ISF wascharacterized following nucleoside transport (NT) blockade elicitedby 10 mmol/L dipyridamole or 10 mmol/L nitrobenzylthioinosine inisolated guinea pig atria, by means of our novel procedure referred toas receptorial responsiveness method (RRM). The RRM provided anindex of the change in [Ado]ISF under NT blockade, namely theconcentration of N6-cyclopentyladenosine (CPA; a relatively stableA1 Ado receptor agonist), which is equieffective with the change in[Ado]ISF regarding the contractility. Our results show that dipyridamoleor nitrobenzylthioinosine produced an elevation in [Ado]ISFat the cardiomyocyte A1 Ado receptors equivalent to about 16 or20 nmol/l CPA, respectively. In addition, nitrobenzylthioinosine wasfound more appropriate for selective NT blockade than dipyridamole.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
atrium
guinea pig
heart
interstitial adenosine
Megjelenés:Journal of Cardiovascular Pharmacology. - 47 : 1 (2006), p. 103-109. -
További szerzők:Zsuga Judit (1973-) (neurológus, pszichoterapeuta, egészségügyi szakmanager) Juhász Béla (1978-) (kísérletes farmakológus) Dér Péter Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos) Tósaki Árpád (1958-) (kísérletes farmakológus, gyógyszerész) Gesztelyi Rudolf (1969-) (kísérletes farmakológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM030254
Első szerző:Kovács Anikó
Cím:Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro / Anikó Kovács, Ildikó Gyönös, János Magyar, Tamás Bányász, Péter P. Nánási, Michael Spedding, Gábor Szénási
Dátum:2001
ISSN:0160-2446
Megjegyzések:The I-Kr blocker EGIS-7229 (S-21407), displays class Ib and class IV effects that may alter its pharmacologic profile compared with those of pure I-Kr blockers. Therefore, the concentration- and frequency-dependent effects of EGIS-7229, and of the I-Kr blockers d,l-sotalol and dofetilide, on the effective refractory period (ERP) were measured in isolated right ventricular papillary muscle of the rabbit in vitro. The effects of these drugs on right ventricular fibrillation threshold (RVFT) at increasing intravenous doses were also determined in anesthetized cats. Dofetilide and d,l-sotalol increased ERP in a concentration-dependent manner (dofetilide: 3-100 nM; d,l-sotalol: 3-100 muM) with strong reverse frequency dependence at high concentrations. EGIS-7229 concentration dependently lengthened ERP at 1-30 muM. Its effect on ERP was clearly reverse frequency dependent at 3 muM, but this feature of the drug diminished at 10 muM and was not apparent at 30 muM The effect of EGIS-7229 (30 muM) on ERP was devoid of reverse frequency dependence as it was more effective (31%) than dofetilide (16 %) at high-pacing rate (3 Hz), whereas it was less effective (50%) than dofetilide (70%) at slow-pacing rate (1 Hz). Reverse frequency-dependent ERP effect of dofetilide (100 nM) was similarly abolished by the addition of lidocaine (30 muM). EGIS-7229 (1-8 mg/kg iv), d,l-sotalol (1-8 mg/kg iv), and dofetilide (10-80 mug/kg iv) caused a dose-dependent increase in RVFT. The minimum effective dose of d,l-sotalol and EGIS-7229 was 1 and 2 mg/kg, respectively. whereas that of dofetilide was 10 mug/kg. EGIS-7229 induced a smaller peak effect in RVFT than sotalol or dofetilide. In conclusion, EGIS-7229 markedly increased refractoriness to electrical stimulation in vitro and in vivo. Compared with pure I-Kr blockers, the benefits of EGIS-7229 seem to be a greater lengthening of effective refractory period at rapid stimulation rates, suggesting a strong antiarrhythmic action, and a smaller effect at slow stimulation rates, suggesting low potential to induce early afterdepolarizations.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Cardiovascular Pharmacology. - 37 : 1 (2001), p. 78-88. -
További szerzők:Gyönös Ildikó Magyar János (1961-) (élettanász) Bányász Tamás (1960-) (élettanász) Nánási Péter Pál (1956-) (élettanász) Spedding, Michael Szénási Gábor
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM101881
Első szerző:Levijoki, Jouko
Cím:The adenylate cyclase activator forskolin potentiates the positive inotropic effect of the phosphodiesterase inhibitor milrinone but not of the calcium sensitizer levosimendan nor of its hemodynamically active metabolites / Levijoki Jouko, Pollesello Piero, Grossini Elena, Papp Zoltán
Dátum:2022
ISSN:0160-2446
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Cardiovascular Pharmacology. - 79 : 6 (2022), p. 827-832. -
További szerzők:Pollesello, Piero Grossini, Elena Papp Zoltán (1965-) (kardiológus, élettanász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM056059
Első szerző:Nagy László (orvos)
Cím:Inotropes and inodilators for acute heart failure : sarcomere active drugs in focus / László Nagy, Piero Pollesello, Zoltán Papp
Dátum:2014
ISSN:0160-2446
Megjegyzések:Acute heart failure (AHF) emerges as a major and growing epidemiological concern with high morbidity and mortality rates. Current therapies in patients with acute heart failure rely on different strategies. Patients with hypotension, hypoperfusion, or shock require inotropic support, whereas diuretics and vasodilators are recommended in patients with systemic or pulmonary congestion. Traditionally inotropic agents, referred to as Ca mobilizers load the cardiomyocyte with Ca and thereby increase oxygen consumption and risk for arrhythmias. These limitations of traditional inotropes may be avoided by sarcomere targeted agents. Direct activation of the cardiac sarcomere may be achieved by either sensitizing the cardiac myofilaments to Ca or activating directly the cardiac myosin. In this review, we focus on sarcomere targeted inotropic agents, emphasizing their mechanisms of action and overview the most relevant clinical considerations.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Cardiovascular Pharmacology 64 : 3 (2014), p. 199-208. -
További szerzők:Pollesello, Piero Papp Zoltán (1965-) (kardiológus, élettanász)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0045
TÁMOP
Kardiológia Kutatócsoport
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM040599
Első szerző:Nieminen, Markku S.
Cím:Effects of Levosimendan on the Energy Balance : Preclinical and Clinical Evidence / Markku S. Nieminen, Piero Pollesello, Gusztáv Vajda, Zoltán Papp
Dátum:2009
Megjegyzések:Levosimendan is a novel inodilator agent, which enhances myocardial performance without substantial changes in oxygen consumption. The combination of positive inotropic and vasodilator effects of levosimendan relates to its Ca-sensitizing and K channel opening effects. Levosimendan is one of the best documented pharmacological agents used in the management of acute heart failure syndromes. Interest in levosimendan has recently been renewed owing to its potential in supporting cardiac function in patients with ischemic heart disease and cardiogenic or septic shock. It has been also demonstrated that levosimendan can be used as a bridge therapy for the perioperative phase of cardiac surgery. The ability of levosimendan to improve myocardial function without substantially increasing oxygen consumption may appear paradoxical but is indeed possible via improved efficacy, not only with regard to the effects on the contractile apparatus of the cardiomyocytes but also when its composite hemodynamic effects are considered. The energy balance equation, therefore, should take into account the effect of levosimendan on all energy-consuming and energy-producing paths. Moreover, levosimendan-evoked KATP channel opening may possess favorable effects on mitochondrial adenosine triphosphate synthesis conferring cardioprotection during ischemic insults.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Cardiovascular Pharmacology and Therapeutics. - 53 : 4 (2009), p. 302-310. -
További szerzők:Pollesello, Piero Vajda Gusztáv (1956-) (kardiológus) Papp Zoltán (1965-) (kardiológus, élettanász)
Pályázati támogatás:K 68363
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

12.

001-es BibID:BIBFORM090883
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero
Dátum:2020
ISSN:0160-2446
Megjegyzések:Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -
További szerzők:Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
   Lásd még:
Egyéb kapcsolat (1)
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.